Highly active antiretroviral therapy (HAART) has proved efficient in increasing CD4 counts in many randomized clinical trials. Because randomized trials have some limitations (e.g. short duration, highly selected subjects), it is still interesting to assess the effect of HAART using observational studies. This is however challenging because treatment is started preferentially in subjects with severe conditions, in particular in subjects with low CD4 counts. The difficulty of assessing treatment effect in observational studies is a general problem arising for other diseases which has been treated using Marginal Structural Models (MSM) relying on the counterfactual formalism.
Summary
Highly active antiretroviral therapy (HAART) has proved efficient in increasing CD4 counts in many randomized clinical trials. Because randomized trials have some limitations (e.g. short duration, highly selected subjects), it is still interesting to assess the effect of HAART using observational studies. This is however challenging because treatment is started preferentially in subjects with severe conditions, in particular in subjects with low CD4 counts. The difficulty of assessing treatment effect in observational studies is a general problem arising for other diseases which has been treated using Marginal Structural Models (MSM) relying on the counterfactual formalism.
Another approach to causality is based on dynamical models. We present first discrete-time dynamic models, based on Linear Increment Models (LIM), which the simplest models consist in one difference equation for CD4 counts while a system of two difference equations allows modeling jointly CD4 counts and viral load. Then we further extend in continuous time with mechanistic models based on ordinary differential equations with random effects (ODE-NLME). Mechanistic models allow incorporating biological knowledge when available which leads to increased power for detecting a treatment effect. Inference in ODE-NLME however is challenging from a numerical point of view, and requests specific methods and softwares. LIM are a valuable intermediary option in terms of consistency, precision and complexity. The different approaches are compared using a simulation study and then applied to two HIV cohorts studies (the ANRS CO3 Aquitaine Cohort and the Swiss HIV Cohort Study).
Introduction
Assessing the effect of a treatment in observational studies is useful because randomized clinical trials have often short durations and often include highly selected subjects. This is however challenging because most of the time the treatment regime is a dynamic process, and covariates history of a subject up to time t may influence treatment given after t, and may also influence the outcome of interest, which induces a time-dependent confounding (Psaty and others, 1999) .
For instance, one may wish to assess the effect of antiretroviral therapy in HIV infected subjects. As CD4+ T-lymphocytes (CD4, in short) are the main target cells of the HIV virus, it is possible to assess the effect of a treatment on the blood concentration of these cells: CD4 counts are measurements of this concentration. In observational studies however, the decision to start an antiretroviral therapy may depend on CD4 counts as well as on other covariates. In this setting, it has been demonstrated that conventional regressions lead to biased estimates of the treatment effect, typically underestimating it and possibly (wrongly) indicating a negative effect. This phenomenon can be called "confounding by indication" (Walker, 1996) . Robins (1994) introduced the structural nested models which can be applied to this problem but difficulties appear in the presence of time-dependent treatment and confounders, see Robins (2000) for theoretical explanations. The marginal structural model (MSM) (Robins and others, 2000) and the g-formula (Westreich and others, 2012) are alternative approaches for treating this problem. In this paper we focus on MSM because estimators based on g-formula generally require more parametric modeling assumptions (Young and others, 2011) . MSM rely on inverse probability weighting; this is based on choosing a causal model in terms of potential responses (which are often counterfactual) to the different treatment regimes. The parameters are estimated through a weighted generalized estimating equation (GEE) . The weights are determined in order to eliminate the bias due to the dependance of treatment attribution on covariates linked to the outcome, and are obtained through a model of treatment attribution. The approach has been applied by Hernán and others (2002) and by Cole and others (2005) for estimating the effect of zidovudine and of highly active antiretroviral therapy (HAART) on CD4 count. Cole and others (2007) , Sterne and others (2005) and Cole and others (2010) used it for estimating the effect of HAART on viral load and on AIDS or death. The estimation of treatment effect comes from the contrast between the expected outcome with and without treatment.
An alternative approach which does not use the potential responses representation is to use dynamic models. The dynamic approach to causality has been pioneered by Granger (1969) , Schweder (1970) , Aalen (1987) , and further developed by Didelez (2008) ; Commenges and Gégout-Petit (2009); Gégout-Petit and Commenges (2010) ; Eichler and Didelez (2010) . Assumptions needed for a causal interpretations of dynamic models have been presented in Arjas and Parner (2004) and Commenges and Gégout-Petit (2015) . Dynamical models in discrete time, and in particular Linear Increment models (LIM), have been proposed by Diggle and others (2007) and Hoff and others (2015) ; Aalen and others (2012) have suggested that such models can be useful for studying HAART effect on CD4 counts or viral load. Discrete-time models however may not be completely satisfactory because the processes of interest most often live in continuous time. Systems of differential equations in continuous time can also be used to model the interaction between HIV and CD4 cells populations. Models based on differential equations, called mechanistic, considerably helped in understanding some important features of the infection: see Perelson (2002) for a review. First, they were used to estimate biological rates in HIV infection: Ho and others (1995) uncovered the high turnover rates of virus and HIV infected CD4 cells.
More interestingly in our setting, it is possible to model the treatment effect from a biological perspective. Introducing random effects allows analyzing a sample of subjects with different parameter values without increasing too much the number of parameters (Wu, 2005; Guedj and others, 2007; Lavielle and others, 2011) . Refined models taking into account pharmacokinetics or pharmacodynamic aspects have also been proposed for treatment monitoring (Prague and others, 2012) . In principle stochastic differential equations could be considered, but they are difficult to handle statistically as well as numerically, and methods are restricted for the moment to rather simple systems: see for instance Picchini and others (2010) or Delattre and others (2013) ; so we restrict to models based on Ordinary Differential Equations (ODE) systems. Fitting ODE-based models with random effects (ODE-NLME) is numerically challenging because of the need to solve the ODE system and to compute numerical integrals which appear in the likelihood. Up to now, mechanistic models have been used to analyze data from clinical trials. Using mechanistic models to estimate the effect of HAART based on data of large observational cohorts is a possibility, that to our knowledge has never been attempted.
The aim of this paper is to compare the dynamic models in discrete (LIM) and continuous time (ODE-NLME) to the MSM in the problem of assessing the causal effect of a treatment on a marker in observational studies. Specifically, we aim at estimating HAART effect in HIV infected patients. We present several possible models and compare them using simulations and real data. In Section 2, we present the statistical models: the naive model, the MSM models, the dynamic models and a mechanistic model. In Section 3, we compare the results of these models in a simulation study, where the data are generated from a complex mechanistic model. Section 4 presents the application of these different models on the data of two cohorts of HIV infected patients: the Swiss HIV Cohort Study (SHCS) and the ANRS CO3 Aquitaine cohort. Section 5 concludes.
Modeling the treatment effect in observational studies

Notations and the naive model
We denote the value of a physiological marker Y for subject i at time t by Y i t . The vector Y t represents the biomarkers for all subjects at time t. The value of a treatment given at time t for subject i is denoted by A i t . For sake of simplicity, we only model two treatment states: A(t) = 0 when treatment is not given, and A(t) = 1 when treatment is given at time t, and we assume that once initiated, the treatment is not interrupted; generalization to different treatment levels is possible. If treatment is started at time t then A In the absence of confounding by indication, a regression of Y t on the history of treatment would give the effect of treatment on the marker. The simplest model would be to regress Y t on cum(Ā t−1 ). It has been noted however that a piecewise linear regression model allowing a change of treatment effect after one year was better suited (Cole and others, 2005) . Thus, the naive model that we consider is our Model 1:
where cumlag(Ā t ) is the cumulative time under treatment up to time t minus one year: cumlag(Ā t ) = max(0, cum(Ā t )−1). The β's are estimated by conventional GEE because it is very likely that the Y t 's are positively correlated, and because we are interested in the population average (Hubbard and others, 2010) . A working correlation structure has to be chosen and the choice may have an impact, not on the bias, but on the efficiency of the estimators (Liang and Zeger, 1986) . However, in presence of time-varying covariates, the independence model should be chosen, otherwise results could be seriously biased, as shown by Pepe and Anderson (1994) . Thus an identity working correlation matrix is used for all GEE models.
Marginal structural models (MSM)
As suggested in the introduction, in observational studies there is often an indication bias using naive models: treatment is given to subjects with low CD4 counts, hence treated subjects tend can be estimated with a suitably weighted GEE. The weights are inverse-probability-of-treatment (IPT); extension to the case with censoring has also been developed (Cole and others, 2005; Cole and Hernán, 2008 ) but this is not be used in this paper. The weights are generally estimated using logistic models for each time and are the product over time of weights deriving from a model of treatment attribution. The causal parameters can be estimated consistently if all the confounders (factors influencing both the outcome of interest and treatment attribution) have been taken into account. Hernán and others (2002) and Cole and others (2005) proposed benchmark models also adjusting for confounders such as time (t) and baseline value of the biomarker (Y 0 ) in the regression. The model for potential outcomes that we consider is the same for our Models 2 and Model 3; it is:
We use the stabilized weights defined as :
where the probabilities are predicted for every subject from a logistic regression depending on a subset of baseline covariates denoted L 0 and their history up to time k denotedL k (L 0 ∈L k ).
The MSM correction compared to Model 1 depends on the correctness of the IPT model. So,
we tried two models of treatment attribution. We define the subsets L for treatment attribution model in Model 2 as baseline and time-varying CD4 count in class (< 200, [200; 400] , > 400)
only. We extend this list for Models 3 to the main potential confounders: viral load in categories (< 401, 401 − 10000 and > 10000), and an indicator of undetectable viral load. In Models 1, 2 and 3, the effect of treatment on CD4 counts during the first year is given by β 1 and the effect after one year of treatment is given by β 1 + β 2 . The impact of treatment on CD4 counts after an infinite time is infinite: it tends to +∞ or −∞ according to the sign of β 1 + β 2 .
Discrete-time dynamical models (LIM)
When using dynamical models, we regress the change in the marker of interest
This fits well with a causal thinking which considers that the change of a process depends on its present, and possibly past, state. The independence assumption for the Z 
where the ε i t 's are iid normally distributed variables with zero expectation. This model can be fitted easily since this is a linear mixed-effects model. In order to account for non equally spaced measurement of biomarkers, we extend the notation to obtain a model which has approximately the same meaning: it is natural to think that the change is be proportional to the time elapsed between two observations, that we note ∆ 
corresponds to an autoregressive model of order one, noted AR (1):
It is well known that is |γ | < 1 this process converges toward a stationary process (in discrete time) with expectation E(
; this is always defined unless γ 1 = 0, as is the case in Model 4 which does not have a finite stationary expectation. The condition amounts to −2 < γ 1 < 0 and to get a positive stationary expectation we must have β 0 > 0. When using a model which has this convergence property, it may not be necessary to have a two-slope model, so we define Model 5 as:
If −2 < β 2 < 0 and β 0 + β 1 > 0, Y tends to a stationary process with expectation − β0+β1 β2 for treated patients.
A more realistic modeling of CD4 counts is to take viral load into account. Here, we make a step toward mechanistic models because we know that the virus concentration and the CD4 concentration are two inter-related processes. Thus, we propose Model 6 based on a system of two difference equations:
(2.5) where W treatment. However, one year and subsequent years increase of CD4, as well as the long term change, are more easily computed by solving the difference equations numerically. The standard deviation of the of CD4 increase could be computed using predictions from the mean value of baseline CD4 and viral load by simulating parameters values from their estimated asymptotic distribution. However, for testing whether the treatment has an effect, it is easier and more powerful to test the hypotheses β 1 = 0 and α 1 = 0, by Wald tests for instance.
Continuous Dynamical models, Mechanistic Models (ODE-NLME)
In reality, biomarkers processes live in continuous time. A natural extension of the dynamical models in discrete time leads to models based on differential equations. We use the "target cells model" that proved to provide a good fit and to have good prediction abilities (Prague and others, 2013) . The combination of the target cells model, a model for inter-individual variability of the parameters, and an observation model specifies our Model 7.
Biological system
We know that only infected cells can produce viruses (V ), so we should distinguish between uninfected (T ) and infected cells (T * ). Moreover, it has been shown that not all CD4 T-cells can be infected with the same probability, so we can distinguish between quiescent cells (Q) and target cells (T ). The instantaneous change of concentrations of these populations at time t, for all real value of t > 0, is given by the ODE system:
The system is graphically represented in Figure 1a . Here, the parameters have biological meanings:
λ is the production rate of new CD4 cells, the µ's are death rates, α and ρ are transition rates between quiescent and activated cells, π is the rate of production of virions by infected cells, and γ is the infectivity parameter. The model assumes that the rate of infection of target T cells is γV t . It has been proved that a patient-by-patient approach such as in Ribeiro and others (2002) is not powerful and allows estimating only a very limited number of parameters. A population approach obtained by introducing random effects (Putter and others, 2002; Huang and others, 2006; Guedj and others, 2007; Lavielle and others, 2011) , allows estimating more parameters. 
Inter-individual variability
Biologically, the causal effect of treatment can be modeled as an effect on the infectivity parameter γ. The parameter γ consequently depends on t through
where we expect β < 0, so that biologically the treatment decreases the infectivity of the virus.
Observation model
One important consequence of using continuous time models is that we must distinguish between the biological system which lives in continuous time and observations which are made at discrete time. We only have observations of total CD4 counts and viral loads at discrete times t ij , Q To make an additive model for measurement error acceptable, we use 4th-root transformation for CD4 and a log 10 transformation for the viral load respectively. Thus, the observation model is: In this Model 7, inference is much more complex and computationally demanding than in discrete-time models. Inference is based on a penalized maximum likelihood approach, and a special Newton-like algorithm has been implemented in the NIMROD program (Prague and others, 2013) . As in Models 5 and 6, assessing the long-term treatment effect in Model 7 is possible by analytically computing the equilibrium point. On the other hand, one year and subsequent years increase of CD4 after treatment initiation can be computed by solving the ODE system
for given values of the random effects. The marginal effect can be computed as the mean of the individual effects in the population. The infectivity parameter gives an indicator of the effect of treatment, and a Wald test can be used to test the no-effect hypothesis "β = 0" .
Simulation study
Design of the simulation
We perform simulations to investigate the properties of the models and methods described above concerning the estimation of causal treatment effect and the long-term prediction of biomarkers. In order to simulate biomarkers trajectories in HIV cohort data, Adams and others (2005) extended the work of Callaway and Perelson (2002) and developed a tool to mimic HIV progression in an individual. They describe a "typical" mechanistic model to be employed for further discussion of mathematical and statistical methodology. This model is much more complex than the one described in Equation 2.6 for Model 7: it includes two co-circulating populations of target cells and immune effectors (such as cytotoxic T-lymphocytes) population, see Figure 1b and Table 1 for a description and the values of parameters chosen for the simulations. Biomarkers trajectories for given values of the parameters are numerically computed by an ODE solver; we use the R package deSolve (Soetaert and others, 2010) . All parameters have inter-individual variability modeled by drawing them from a normal law (with mean values listed in Table 1 and variances chosen to obtain a variation coefficient of 50%). Thus, the simulated patients have various biomarkers trajectories because they have different parameters values.
Patients' parameters are related with steady state values for biomarkers without treatment;
as there is no analytic solution for this system, this steady state may be found by running the solver long enough. Random effects are simulated so that the steady state baseline distribution of CD4 counts and viral load is consistent with the baseline values distribution found in Aquitaine cohort and SHCS dataset (see Table 3 ). An observation model is also simulated with visits every 3 months (90 days). We generate observations according to the same model as (2.8); the standard deviations of the measurement errors are chosen approximately equal to those estimated from real data σ V L = 0.6 and σ CD4 = 0.1 respectively. Viral load is artificially censored at the level of 50 copies/mL. Treatment assignment is done by simulating a CD4 count assessment at every visit (every 3 months) and by fixing a probability of treatment attribution depending on the observed CD4 count. We took empirical probabilities from the Aquitaine cohort and SHCS dataset: treatment is attributed in 2%, 28% or 47% of the cases if CD4 count is > 400, [400, 200] or < 200. Neither confounder nor drop-out is considered. We simulate n=200 and n=1500 patients to look at small and large sample properties. Table 4 gives a general description of both simulated and real data sets: no major inconsistency in descriptive statistics values appears between simulated and real real cohort data sets.
Evaluating the true treatment effect in the simulation
It is possible to get an analytic value of the treatment effect in the simulated model. For computing it, we build two datasets without adding noise on the biomarkers. The first dataset (D1) consists in the true value (without noise) of the biomarkers trajectories according to the observed schedule of treatment for each simulated patient. The second dataset (D2) is a counterfactual dataset where we simulate patients' biomarkers trajectories without noise if no treatment is attributed. We define the "mean causal effect in treated patients", which is the real increase of CD4 in patients before 1 year, between years 1 and 2 and after an infinite time when treatment was initiated 
Practical concerns
For Models 1-3 which are fitted by ordinary or weighted GEE, we used the R software and the function geeglm in the package geepack (Halekoh and others, 2006) . Independence working correlation matrices are used. For models 2 and 3, weights are computed with the function ipwtm in the package ipw (van der Wal and Geskus, 2011) but could have been implemented from scratch. Models 4-6 are fitted using non linear mixed effect models package lme4 (Bates and others, 2014), particularly the function lmer. In Model 7, in order to avoid identifiability issues, we use a priori knowledge on mechanistic parameters: the priors are set according to past estimates of the biological parameters in the literature (Prague and others, 2012) and are given in Table 2 . Mechanistic models are fitted using NIMROD (Prague and others, 2013) .
Results of the simulation
We run the analysis of Models 1-7 proposed in Section 2; results are presented in Table 5 for the simulated data set n=200 and n=1500. All results and conclusions are similar in small and large sample. First, we notice that the naive Model 1 largely underestimates the treatment effect. This is corrected by the MSM Models 2 and 3. Figure 3 shows the box-plot of the weights for Model 3 estimated by the treatment attribution model using a logistic regression; we found values close to the theoretical probabilities of treatment attribution. Models 2 and 3 give similar results because the true model of weight is only based on CD4 count. Thus in the simulation, the model for treatment attribution is no better specified in Model 3 than in Model 2. Model 4 also gives good estimates of the mean causal effect in treated patients both for the first year and subsequent years. However, we can notice that long-term increase of CD4 is infinite in Models 1 to 4. Models 5-7 have an equilibrium point which makes it possible to consider the long-term causal effect of treatment. All dynamic models give a correct estimate of the long-term effect of the treatment.
However, the misspecification of the models can induce biases. Actually, the initial increase in CD4
during the first year is not correctly caught by Model 5. Models 6 and 7 which both incorporate the dynamics of viral load give a correct estimation of the increase of CD4 count. Moreover, both models allow a qualitative interpretation of the pathway of action of treatment with a mediation through the decrease of the viral load. Model 7 allows a more detailed mechanistic interpretation of the infection and provides estimates of important biological parameters. Table 6 shows the a posteriori means and standard deviations for the log-transformed biological parameters. To some extent, these values can be compared to the generating values in Table 1 . For instance, the viral clearance is 13 virions/day and is estimated at around 7 virions/day with our misspecified model.
Even if all models found a significant effect of treatment on CD4 counts in the first year, the Z-statistics for the no-effect hypothesis are larger or much larger for dynamical models (LIM and ODE-NLME models) than for the GEE-based models, indicating more power to reject the null hypothesis.
Real data
The Aquitaine cohort and the Swiss cohort
Real data analysis is based on datasets from two large cohorts: the ANRS CO3 Aquitaine cohort (Thiébaut and others, 2000) and the Swiss HIV Cohort Study (SHCS) (Schoeni-Affolter and others, 2010). We compare the estimates of the effect of HAART on CD4 counts obtained by the naive, the MSM and the dynamic models.
For the Aquitaine cohort, the raw dataset includes 4541 patients and a total of 110,663
observations. For the SHCS, we use the same dataset as previous methodological work (Sterne and others, 2005; Gran and others, 2013) which includes 2161 patients and a total of 77,838
observations. Similarly to Cole and others (2005) we take a subsample of patients who are alive, HIV positive, yet untreated and under follow-up in April 1996 when HAART became available.
All patients taking ARV in mono-or bi-therapy instead of HAART are excluded. Once a patient is on any therapy, we assume he or she remains on it. For each of them, the follow-up begins with the first visit after April 1996 and ends with 1) the last visit at which he or she was seen alive, 2) the last visit before patient discontinued the study, or 3) April 2005, whichever comes first. Patients with at least 2 observations are included. Table 7 show the patient selection flow chart. In Sterne and others (2005) , last observation carried forward analysis (LOCF) was used to analyze SHCS to account for missing visits. However, Cook and others (2004) showed that this approach is not optimal and may lead to biases. Thus, we prefer to make the assumption that data are MCAR. Thus, we delete all observations where viral load or CD4 count were missing. Table 4 gives basic descriptive statistics. Table 8 displays the results we obtained for the treatment effect on CD4 counts. Computation times were less than 1 minute on a classical laptop for Models 1 to 6. Fitting Model 7 took about 10 hours of parallel computing over 100 cores.
Results from the cohort data
The naive Model 1, not correcting for treatment attribution, indicates a small and nonsignificant increase of CD4 for SHCS cohort, and a significant negative effect for the Aquitaine Cohort; this illustrates the need for correcting for treatment attribution. Models 2 and 3 have different weights but show rather similar results, probably because treatment initiation was mainly driven by observed CD4 count. Both models yield a significant increase of CD4 counts for one year of treatment and after one year. The one-year increase however is much smaller for the Aquitaine cohort than for the SCHS. This is potentially due to the fact that the overall percentage of treatment is very different between the two cohorts (34% in SHCS vs. 64% in the Aquitaine cohort) and inverse probability weighting techniques are known to be highly sensitive to the models for treatment attribution. The dynamical models (LIM and ODE-NLME), especially Models 6 and 7, show a better consistency between the two cohorts.
Model 6 is interesting because it dissociates the effect of the treatment on CD4 and on viral load. We see that treatment has a non significant effect on CD4 change for the Aquitaine cohort (Z-stat=1.53); although this effect is significant for the SHCS (Z-stat=5.0) the absolute values of the Z-statistics are much higher for the effect on the viral load. This is consistent with the type of action of antiretroviral treatments: the increase of the CD4 count is essentially mediated by the decrease in viral load, which is the direct effect of antiretroviral treatments. Such biological knowledge is incorporated in Model 7 where the treatment acts on the infectivity parameter.
In view of the Z-statistics obtained by a Wald test of the hypothesis β = 0 in 2.7, the power obtained in Model 7 is very high. Such high values are rarely encountered in statistical analysis.
To confirm the very low p-values that can be found in this model, we performed a log likelihood ratio test. We ran the NIMROD analysis again fixing β = 0 and obtained log-likelihood under the null hypothesis. We found: LL = −2 * −13836 + 2 * −12561 = 2550 for the SHCS and LL=-2*-25211+2*-24579=1264 for the Aquitaine cohort, also yielding to a very low p-value. Finally, Model 7 gives an insight into the value of the biological birth and death rates of cells during the infection (Table 9 ). The estimates from the two datasets are rather consistent in the sense that they have the same order of magnitude, although a formal comparison would show that several parameters are different, potentially due to different characteristics of the patients in the two cohorts.
Finally, a simple way to look at these results and to compare them, is to consider the mean evolution of CD4 along time. Figure 4 represents the predicted CD4 count with Models 1, 3, 6
and 7 for treated patients starting at baseline with 365 CD4 cells/mm 3 and a viral load of 4.4 log 10 cp/mL (which are approximately the mean values at treatment initiation in the cohorts).
For Models 1 to 3, these curves are deterministic, which is not the case for Models 4 to 7 that have random effects. For these latter models, we computed the mean predicted curves depending on the value of the random effect, which have to be set to values compatible with the baseline condition for values of biomarkers. In order to set them, in both case, we computed the equilibrium point of the system without treatment and solved the system of equations. This was possible since we had two random effects and two conditions equations. In Figure 4 , it is clear that the naive Model 1 badly under-estimates the effect. Both Models 1 and 3 are highly unstable, whereas Model 6 or the mechanistic Model 7 are more consistent between the two studies and have equilibrium points. Model 6 however is way faster and easier to run than Model 7.
Conclusion
We described and compared a naive model, two MSM and four dynamic models (2 LIM and 2 ODE-NLME) for estimating the treatment effect of HAART on CD4 in observational studies. We tried such models on simulated data and on the real data of the Swiss HIV Cohort Study and of the Aquitaine cohort study. The naive regression model (Model 1) strongly underestimated the effect of the treatment. The MSM models (Models 2 and 3) corrected this misleading result but failed to reach significance or were unstable among studies. In contrast, the discrete dynamic models LIM (Model 4, 5 and 6) gave rather good estimates and appear to have a higher power.
Models 6 and 7, which jointly model CD4 and viral load gave the most consistent results, with a richer interpretation since they take into account that the effect of HAART on CD4 is mediated by viral load. However, these models may sometimes be too rigid, as was the case for Model 5 which wrongly caught the dynamics. The mechanistic model ODE-NLME (Model 7) directly incorporates biological knowledge. This leads to a more powerful test for the parameter of interest.
Moreover, in the ODE-NLME approach, we distinguish the system living in continuous time and observations taken at discrete times. One of the advantages of this distinction is that we would be able to use the data as they are collected and thus a greater amount of information: with discretetime models we must have approximately equally-spaced observations, which rarely occurs in real observational studies. Moreover, ODE-NLME may take into account more data since the likelihood may be computed if either the CD4 count or the viral load is observed. Thus, less data are omitted which leads to both increased power and less biases due to selection. However, results may be sensitive to misspecification even if the simulations in this paper suggest that misspecification (Target cell model versus Adams and others (2005) model) does not necessarily prevent to obtain a reasonable and significant estimate of treatment effect. All the discrete-time models can be easily fitted with classical softwares. The drawback of ODE-NLME is that it is numerically challenging and requires special software running on cluster computers.
More generally, MSM provide consistent estimates but lack precision. Adding more information, as we did with dynamic modeling, improves precision at the risk of increased bias; we encounter here the well known bias-variance trade off issue. This result is consistent with findings in Fitzmaurice and others (2008) showing that the most parametric a model is the most sensitive it is to bias. In other words, the MSM is fairly robust to bias from misspecification of a model, but may be an impractical method in many applications because of poor power that results in uninformative and wide confidence intervals (Hernán and others, 2006) . On the other hand, dynamical models provide more efficient estimates, but require a better specification of the dynamical mechanism which may be challenging. Although mechanistic models are already used in HIV, infection diseases and oncology, another limitation is that we do not always have sufficient biological knowledge for constructing a mechanistic model for any application. Altogether, this study showed that a dynamical approach for estimating the treatment effect on large observational cohorts is possible, with either discrete or continuous-time models, and may have better efficiency than marginal structural models.
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γ -1.12 0.014 -79.3 -1.03 0.003 -295.6 †Estimates for treatment effect (β) are significant at level 10% if the absolute value of Z-stat is greater than 1.64 and significant at level 5% if the absolute value of Z-stat is greater than 1.96.
To be compared with mean treatment effect in treated for (< 1 year; > 1 year; ∞): benchmarks values are (350;12;370) for these simulations. 
